Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Down 3.2% - Here's Why

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) fell 3.2% during mid-day trading on Thursday . The company traded as low as $5.96 and last traded at $5.98. 3,884,146 shares changed hands during mid-day trading, a decline of 84% from the average session volume of 25,000,162 shares. The stock had previously closed at $6.17.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on RXRX. Cowen reaffirmed a "hold" rating on shares of Recursion Pharmaceuticals in a research report on Friday, February 28th. KeyCorp reduced their price objective on shares of Recursion Pharmaceuticals from $12.00 to $10.00 and set an "overweight" rating for the company in a research report on Wednesday, January 8th. Needham & Company LLC reaffirmed a "buy" rating and issued a $11.00 price objective on shares of Recursion Pharmaceuticals in a research report on Thursday, February 6th. Finally, Leerink Partners reduced their target price on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a "market perform" rating for the company in a research report on Friday, February 28th. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Hold" and a consensus target price of $8.25.

Recursion Pharmaceuticals Stock Up 6.9 %

The stock's 50-day moving average price is $7.54 and its two-hundred day moving average price is $7.02. The stock has a market capitalization of $2.55 billion, a P/E ratio of -4.15 and a beta of 0.85. The company has a current ratio of 4.35, a quick ratio of 4.35 and a debt-to-equity ratio of 0.04.

Remove Ads

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last released its earnings results on Friday, February 28th. The company reported ($0.53) earnings per share for the quarter, missing analysts' consensus estimates of ($0.36) by ($0.17). The company had revenue of $4.60 million for the quarter, compared to the consensus estimate of $19.04 million. Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The firm's revenue was down 57.8% on a year-over-year basis. During the same period in the prior year, the company earned ($0.42) earnings per share. As a group, research analysts expect that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the business. Integrated Advisors Network LLC boosted its holdings in Recursion Pharmaceuticals by 36.8% in the 4th quarter. Integrated Advisors Network LLC now owns 17,588 shares of the company's stock worth $119,000 after buying an additional 4,731 shares during the period. GF Fund Management CO. LTD. bought a new position in Recursion Pharmaceuticals in the 4th quarter worth approximately $54,000. CSS LLC IL bought a new position in Recursion Pharmaceuticals in the 4th quarter worth approximately $366,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in Recursion Pharmaceuticals by 5.5% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 2,259,178 shares of the company's stock worth $15,272,000 after buying an additional 118,428 shares during the period. Finally, Vident Advisory LLC bought a new position in Recursion Pharmaceuticals in the 4th quarter worth approximately $80,000. 89.06% of the stock is owned by institutional investors.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.